Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Transcode Therapeutics Inc (RNAZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: RNAZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -93.07% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.41M USD | Price to earnings Ratio - | 1Y Target Price 20 |
Price to earnings Ratio - | 1Y Target Price 20 | ||
Volume (30-day avg) 10152419 | Beta 1.15 | 52 Weeks Range 0.52 - 66.33 | Updated Date 03/27/2025 |
52 Weeks Range 0.52 - 66.33 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5571.72 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -129.43% | Return on Equity (TTM) -490.03% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1312595 | Price to Sales(TTM) - |
Enterprise Value -1312595 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.59 | Shares Outstanding 696249 | Shares Floating 411592 |
Shares Outstanding 696249 | Shares Floating 411592 | ||
Percent Insiders 0.15 | Percent Institutions 0.67 |
Analyst Ratings
Rating 4 | Target Price 20 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Transcode Therapeutics Inc
Company Overview
History and Background
Transcode Therapeutics Inc., founded in 2010, is a clinical-stage biopharmaceutical company focused on developing RNA therapeutics for cancer and other diseases. It's focused on delivering novel therapeutics to patients.
Core Business Areas
- RNA Therapy Development: Develops proprietary RNA therapeutics using its TTX delivery platform for targeted drug delivery to cancer cells.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its RNA therapeutics in treating various cancers.
Leadership and Structure
The company is led by Michael Dudley, President & CEO, and has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- TTX-MC138: An RNAi therapeutic targeting microRNA-10b for metastatic cancer treatment. It is in Phase 0 clinical trials. Limited market share data available due to its early stage. Competitors include companies developing similar RNAi therapies, such as Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR).
- TTX-siPDL1: siRNA-based product candidate, designed to shut down PD-L1 expression in tumors. The Company plans to start Phase 0 clinical trial. Limited market share data available due to its early stage. Competitors include companies developing similar siRNA therapies, such as Alnylam Pharmaceuticals (ALNY) and Arrowhead Pharmaceuticals (ARWR).
Market Dynamics
Industry Overview
The RNA therapeutics market is growing rapidly, driven by advances in RNA delivery technologies and the potential to treat a wide range of diseases. It's a competitive landscape with both large pharmaceutical companies and smaller biotech firms.
Positioning
Transcode Therapeutics is a relatively small player in the RNA therapeutics market, focusing on its proprietary TTX delivery platform to differentiate itself. Its competitive advantage lies in its targeted drug delivery system.
Total Addressable Market (TAM)
The TAM for RNA therapeutics is estimated to reach billions of dollars, with significant growth expected in the coming years. Transcode is positioned to capture a share of this market through successful clinical trials and commercialization of its products.
Upturn SWOT Analysis
Strengths
- Proprietary TTX delivery platform
- Focus on RNA therapeutics
- Experienced management team
- Early stage clinical trials underway
Weaknesses
- Limited financial resources
- Early-stage clinical development risks
- Small market capitalization
- Dependence on successful clinical trial outcomes
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Increased funding for RNA therapeutics research
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Economic downturn affecting funding for biotech companies
Competitors and Market Share
Key Competitors
- ALNY
- ARWR
- MRNA
Competitive Landscape
Transcode Therapeutics faces intense competition from larger, more established companies in the RNA therapeutics market. Its success depends on differentiating its TTX delivery platform and achieving positive clinical trial results.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Transcode Therapeutics Inc. has not demonstrated significant historical growth in revenue or profitability as they are still in Phase 0 Clinical Trials. Growth is dependent on successful future development.
Future Projections: Future growth projections are highly speculative and dependent on successful clinical trials and regulatory approvals. Analyst estimates vary widely due to the inherent risks in biotech investing.
Recent Initiatives: The most recent initiative is the continued development of its TTX platform and advancement of TTX-MC138 and TTX-siPDL1 through clinical trials.
Summary
Transcode Therapeutics Inc. is a clinical-stage biopharmaceutical company with a promising RNA therapeutics platform, but it faces significant challenges, including limited financial resources and competition from larger companies. Its success hinges on achieving positive clinical trial results and securing partnerships. The company's innovative TTX delivery platform provides a potential competitive advantage, but its future is uncertain. The early stage of its clinical development presents both risks and opportunities.
Similar Companies
- ALNY
- ARWR
- MRNA
- CRIS
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Transcode Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-07-08 | Interim CEO, CFO, President, VP of Administration & Director Mr. Thomas A. Fitzgerald M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | |
Full time employees 8 | |||
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.